UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~February~~March 2026

Commission File Number: 001-41421

Alvotech
(Translation of registrant's name into English)

9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

Incorporation by Reference

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”) excluding ~~Exhibit~~Exhibits 99.1, ~~attached~~99.2 and 99.3 attached hereto, ~~shall~~ shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits 99.1, 99.2 and 99.23 to this Report are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall ~~they~~it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

~~Company~~Press ~~Announcement~~Release

On ~~February~~March 2718, 2026, Alvotech ~~announced~~issued ~~that~~a ~~according~~Press toRelease ~~forms~~announcing ~~filed~~ the ~~Luxembourg~~Financial ~~Commission~~Results ~~de Surveillance du Secteur Financier (CSSF) regarding transactions of managers~~ and ~~closely~~Business ~~associated~~Update ~~persons,~~for ~~ATP~~Q4 ~~Holdings~~2025 ~~ehf. had announced the sale of 2,701,617 shares in Alvotech on January 30, 2026,~~ and ~~Aztiq Pharma Partners S.à r.l. ("Aztiq") announced~~ the ~~acquisition~~full ~~of 2,701,617 shares in Alvotech on January 30, 2026~~year. ~~The two announcements were related to the same transaction, and the transaction price~~ ~~was~~A ~~USD~~copy ~~4.74 per share. ATP Holdings ehf. belongs to the Aztiq group and the transaction was thus a transfer~~ of ~~shares within~~ the ~~group. Copies~~Press ofRelease ~~the~~is ~~forms are~~ furnished herewith as ~~exhibits~~Exhibit 99.1 ~~and 99~~.2.

Earnings Report and Presentation

On March 18, 2026, Alvotech made public a more detailed earnings report with Financial Results and Business Update for Q4 2025 and the full year. A copy is furnished herewith as Exhibit 99.2. The Company also made public its Earnings Call Presentation. A copy is furnished herewith as Exhibit 99.3.

EXHIBIT INDEX

Exhibit Number		Description
99.1		~~Notification~~Press ~~and~~Release ~~public~~dated ~~disclosure~~March of18, ~~transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)~~2026
99.2		~~Notification~~Earnings ~~and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (HOS-2 form)~~Report
99.3		Earnings Call Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Alvotech
		(Registrant)
Date: February 27, 2026		/s/ Tanya Zharov
Date: March 19, 2026		/s/ Tanya Zharov
		Tanya Zharov
		General Counsel

Filing Compare · Alvotech